These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36435064)
1. Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. Abd El-Fattah EE; Selim HM Int Immunopharmacol; 2022 Dec; 113(Pt B):109475. PubMed ID: 36435064 [TBL] [Abstract][Full Text] [Related]
2. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. Rodríguez MM; Fiore E; Bayo J; Atorrasagasti C; García M; Onorato A; Domínguez L; Malvicini M; Mazzolini G Mol Ther; 2018 Dec; 26(12):2738-2750. PubMed ID: 30301668 [TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation. Fang X; Yan Q; Liu S; Guan XY Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293184 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099 [TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway. Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741 [TBL] [Abstract][Full Text] [Related]
6. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882 [TBL] [Abstract][Full Text] [Related]
7. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. Huang WC; Tung SL; Chen YL; Chen PM; Chu PY BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298 [TBL] [Abstract][Full Text] [Related]
8. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778 [TBL] [Abstract][Full Text] [Related]
9. The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma. Zhang J; Song Q; Wu M; Zheng W Curr Med Chem; 2021; 28(1):93-109. PubMed ID: 32000636 [TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594 [TBL] [Abstract][Full Text] [Related]
11. Immune vulnerability of ovarian cancer stem-like cells due to low CD47 expression is protected by surrounding bulk tumor cells. Chang CL; Wu CC; Hsu YT; Hsu YC Oncoimmunology; 2020 Aug; 9(1):1803530. PubMed ID: 32923164 [TBL] [Abstract][Full Text] [Related]
12. A quartet of cancer stem cell niches in hepatocellular carcinoma. Balaji N; Kukal S; Bhat A; Pradhan N; Minocha S; Kumar S Cytokine Growth Factor Rev; 2024 Oct; 79():39-51. PubMed ID: 39217065 [TBL] [Abstract][Full Text] [Related]
13. Blocking CD47 promotes antitumour immunity through CD103 Wang S; Wu Q; Chen T; Su R; Pan C; Qian J; Huang H; Yin S; Xie H; Zhou L; Zheng S J Hepatol; 2022 Aug; 77(2):467-478. PubMed ID: 35367532 [TBL] [Abstract][Full Text] [Related]
14. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. Liu YC; Yeh CT; Lin KH Cells; 2020 May; 9(6):. PubMed ID: 32466488 [TBL] [Abstract][Full Text] [Related]
15. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083 [TBL] [Abstract][Full Text] [Related]
16. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Lee TK; Guan XY; Ma S Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):26-44. PubMed ID: 34504325 [TBL] [Abstract][Full Text] [Related]
17. 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Rodríguez MM; Onorato A; Cantero MJ; Domínguez L; Bayo J; Fiore E; García M; Atorrasagasti C; Canbay A; Malvicini M; Mazzolini GD Sci Rep; 2021 Mar; 11(1):6310. PubMed ID: 33737571 [TBL] [Abstract][Full Text] [Related]
18. Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. Yao H; Liu N; Lin MC; Zheng J Cancer Lett; 2016 Sep; 379(2):213-9. PubMed ID: 27108065 [TBL] [Abstract][Full Text] [Related]
19. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Wu B; Shi X; Jiang M; Liu H Mol Cancer; 2023 Feb; 22(1):38. PubMed ID: 36810098 [TBL] [Abstract][Full Text] [Related]
20. Road to stemness in hepatocellular carcinoma. Flores-Téllez TN; Villa-Treviño S; Piña-Vázquez C World J Gastroenterol; 2017 Oct; 23(37):6750-6776. PubMed ID: 29085221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]